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Abstract: Producing antimicrobials is a common adaptive behavior shared by many microorganisms,
including marine bacteria. We report that SF214, a marine-isolated strain of Bacillus pumilus, produces
at least two different molecules with antibacterial activity: a molecule smaller than 3 kDa active
against Staphylococcus aureus and a molecule larger than 10 kDa active against Listeria monocytogenes.
We focused our attention on the anti-Staphylococcus molecule and found that it was active at a wide
range of pH conditions and that its secretion was dependent on the growth phase, medium, and
temperature. A mass spectrometry analysis of the size-fractionated supernatant of SF214 identified
the small anti-Staphylococcus molecule as a pumilacidin, a nonribosomally synthesized biosurfactant
composed of a mixture of cyclic heptapeptides linked to fatty acids of variable length. The analysis
of the SF214 genome revealed the presence of a gene cluster similar to the srfA-sfp locus encoding
the multimodular, nonribosomal peptide synthases found in other surfactant-producing bacilli.
However, the srfA-sfp cluster of SF214 differed from that present in other surfactant-producing strains
of B. pumilus by the presence of an insertion element previously found only in strains of B. safensis.
Keywords: SF214; B. pumilus; antimicrobials; lipopeptides; surfactants; surfactin; pumilacidin
1. Introduction
The emergence of pathogenic antibiotic-resistant bacteria urges for an increased attention to
the identification and characterization of new antimicrobials. Marine organisms have remarkably
contributed to the discovery and production of novel antimicrobials, and in general, of biomolecules
of pharmaceutical relevance. Indeed, over 50% of all drugs approved in the U.S. between 1981 and
2002 are based on either marine bioactive compounds or their synthetic analogs [1]. However, for its
enormous biodiversity, the marine environment is still considered a largely unexplored source of
antimicrobial agents [1,2]. Sponges, marine algae, and bacteria all produce a large variety of secondary
metabolites of remarkable chemical diversity with potential antimicrobial activity [2]. In recent
years, terpenoids, steroids, phenolic compounds, alkaloids, polyketides, and peptides produced by
marine organisms have shown antibacterial, antiviral, and antifungal activities [2]. Bacterial peptides
and lipopeptides with antimicrobial activity are probably the most promising molecules for future
biomedical applications because of their relative ease of overproduction and purification. Over the
years, several examples of peptides and lipopeptides produced by marine bacteria and showing
antimicrobial activities have been reported. These include the cyclic lipopeptides maribasins A and B,
produced by Bacillus marinus and active against several phytopathogens and fungi [3]; the lipopeptide
tauramamide, produced by Brevibacillus laterosporus and selectively active against Enterococcus cells [4];
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and a thiopeptide produced by Nocardiopsis sp. TP-1161 and active against a wide range of bacteria [5].
Often, the synthesis of antimicrobial peptides and lipopeptides does not rely on the translational
machinery, but on multimodular enzymes, the nonribosomal peptide synthases (NRPS) [6]. These
enzymatically produced peptides are biosurfactants with antimicrobial activity and often contain
cyclic structures, D-amino acids, and various modifications such as N-methyl and N-formyl groups or
glycosylation, acylation, or hydroxylation [7]. The peptide moiety of these biosurfactants is generally
formed by 7–15 residues (hydrophilic head) and is bound to a fatty acid (hydrophobic tail) of variable
lengths [8–10]. Various species of the Bacillus genus produce similar nonribosomal lipopeptides
grouped in the surfactin, iturin, or fengycin families [11]. Members of the surfactin family are
surfactin, produced by strains of B. subtilis and B. amyloliquefaciens; lichenysin, produced by strains
of B. licheniformis; and pumilacidin, produced by strains of B. pumilus and B. safensis [12]. The best
characterized of these is surfactin, a mixture of cyclic lipopeptides formed by a heptapeptide with
the sequence Glu–(Leu/Ile/Val)–Leu–(Leu/Ile/Val)–Asp–Leu–(Leu/Ile/Val) and a beta-hydroxy
fatty acid with chains of length ranging from 13 to 16 carbons and differing mostly in the fatty acid
substitutions [12]. While surfactins have a wide spectrum of activity against various Gram-positive
and Gram-negative bacteria [13,14], pumilacidins have antiviral [15] and antimotility [16] activities,
but no data are currently available on their antibacterial activity.
We screened a collection of marine-isolated bacteria, all Gram-positive, aerobic endospore formers
belonging to the Bacillus genus, to search for strains producing molecules with antimicrobial activity
against a panel of target bacteria. The only strain in our screen that showed antibacterial activity
was Bacillus pumilus SF214, a previously characterized strain, shown to produce a water-soluble
yellow-orange pigment [17]. The still-uncharacterized pigment is essential to protect SF214 cells
against oxidative stress and its synthesis is highly regulated, with a maximum of production in
minimal media at 25 ◦C and during the stationary phase of growth [18,19]. The aim of this work was
then to provide a characterization of the antibacterial molecules produced and secreted by SF214 and
of the genes involved in their biosynthesis.
2. Results and Discussion
2.1. SF214 Secretes Two Antimicrobials Active Against Staphylococcus aureus or Listeria monocytogenes
In order to identify new molecules with antimicrobial activity, we used a collection of fifteen
Bacillus strains all isolated from marine samples (Supplementary Materials Table S1). All strains were
grown for 16 h at 30 ◦C in LB (Luria-Bertani) medium, the culture supernatants were filter-sterilized,
and 10 µL of each supernatant was used for antimicrobial plate assays with a panel of target
bacterial strains. Only one of the fifteen strains tested, SF214, showed antimicrobial activity against
Staphylococcus aureus and Listeria monocytogenes (Supplementary Materials Table S2). To characterize
the antimicrobial activity of SF214, the supernatant was size-fractionated and the various fractions
tested in antimicrobial plate assays against the two sensitive target bacteria. While the molecule active
against S. aureus was in the fraction smaller than 3 kDa, the one active against L. monocytogenes was in
the fraction of molecules larger than 10 kDa (Figure 1), indicating that SF214 produces and secretes at
least two different molecules with antimicrobial activity.
2.2. Production of Both Antimicrobials Is Strictly Regulated
SF214 was grown at various temperatures and in different growth media. The supernatants
of the various growth experiments were size-fractionated and the fractions smaller than 3 kDa and
larger than 10 kDa tested against S. aureus and L. monocytogenes, respectively. As shown in Table 1,
the anti-Staphylococcus activity was stronger in supernatants obtained with minimal (S7) medium than
in rich (LB or BHI, Brain Heart Infusion) or in sporulation-inducing (DS, Difco Sporulation) media and
was stronger in supernatants of cell growth at 25 ◦C than at 30 or 37 ◦C. The anti-Listeria activity was
similarly strong in supernatants obtained with BHI and S7 media, while it was slightly less strong in
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LB or DS media. In the minimal S7 medium, the anti-Listeria activity was similarly strong at 25 ◦C and
30 ◦C and slightly less strong at 37 ◦C (Table 1).
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activity identical to that of the wild-type strain (data not shown), indicating that the pigment and the 
antimicrobial molecules were independent molecules. 
Figure 1. Antimicrobial plate assays. Fractions of Bacillus pumilus SF214 supernatant were tested
against target bacteria. The fraction containing molecules smaller than 3 kDa was active against
S. aureus and not against L. monocytogenes, while the fraction containing molecules larger than 10 kDa
was active against L. monocytogenes and not against S. aureus.
Table 1. Production of antimicrobials at various growth conditions.
Medium Temperature (◦C)
Supernatant Activity a
> 10 kDa against
L. monocytogenes
Supernatant Activity a
< 3 kDa against
S. aureus
LB (Luria-Bertani) 25 7 5
BHI (Brain Heart
Infusion) 25 10 5
DS (Difco
Sporulation) 25 7 5
S7 25 10 10
S7 30 10 7
S7 37 5 5
BHI broth was supplemented with 0.1% glucose. a Diameter (mm) of the inhibition halo in plate assays.
Production of the two antimicrobial molecules was also analyzed during growth in S7 medium at
25 ◦C. As shown in Figure 2, while the anti-Listeria molecule was produced during the exponential
and stationary growth phases and the increase of activity paralleled the increase in the number of
cells, production of the anti-Staphylococcus molecule only started in the late stationary growth phase
and continued during the stationary phase, revealing the typical pattern of synthesis of secondary
metabolites. The production profile of the antimicrobial smaller than 3 kDa resembled that of the
pigment produced by SF214 cells. Indeed, the pigment was also produced in the late stationary phase
of growth, preferentially at 25 ◦C in minimal (S7) medium [17]. However, single mutants of SF214
that did not produce [18] or produced a larger amount [19] of pigment showed an anti-Staphylococcus
activity identical to that of the wild-type strain (data not shown), indicating that the pigment and the
antimicrobial molecules were independent molecules.
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Table 2. Effect of pH on antimicrobial activity.
pH
Supernatant Activity a < 3 kDa against S. aureus
1 h 5 h
2 7 7
4 10 10
7 10 10
10 10 10
13 10 10
a Diameter (mm) of the inhibition halo in plate assays.
Table 3. Effects of heat, chemicals, and enzymes o antimicrobial activity.
Treatment Supernat t Activity b < 3 kDa against S. aureus
None 10
Trypsin a 10
Proteinase K a 10
DNase a 10
Ribonuclease A a 10
Acetone c 10
Ethyl alcohol c 10
Chloroform c 10
Toluene c 10
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Table 3. Cont.
Treatment Supernatant Activity b < 3 kDa against S. aureus
Incubation (15 min) at:
60 ◦C 10
80 ◦C 10
100 ◦C 5
a The enzyme concentration was 100 µg/mL [20]. b Diameter (mm) of the inhibition halo in plate assays. c A 10%
(v/v) concentration was used.
2.4. Purification and Chemical Characterization of the Anti-Staphylococcus Molecule
The supernatant fraction active against S. aureus was extracted with chloroform. Both aqueous
and organic phases were tested for antimicrobial activity against S. aureus, revealing that the organic
phase was endowed with the antimicrobial activity. The 1H NMR spectrum suggested the presence
of a complex mixture of compounds (data not shown). To investigate the nature of the antimicrobial
molecule, we performed a preliminary purification of the bioactive compound by using a C18 reverse
phase column and eluted with acetonitrile and water in different ratios. The obtained fractions were
tested to evaluate the antimicrobial activity on S. aureus. The results clearly indicated that the active
fraction was eluted with the 50% acetonitrile solution. The 1H NMR spectrum of the active fraction
(Figure 3) suggested the presence of long hydrocarbon chains, due to the intense signals in the range of
0.5–1.5 ppm. In addition, signals appearing between 7.0 and 8.5 ppm strongly suggested N–H protons,
that together with signals around 4 ppm, indicated a peptide backbone (Figure 3) [9,15].
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Figure 3. NMR spectrum. 1H NMR spectrum of the active fraction, recorded at 298 K, in DMSO, at
600 MHz.
To test if the compounds were lipopeptides, a positive ion mass spectrometry experiment was
performed by a MALDI-TOF instrument. The spectrum indicated the presence of several clusters of
signals, within the range of m/z 1000–1200. By comparing the m/z values with the mass numbers
reported for the lipopeptides commonly produced from Bacillus strains, we found that the signals at
m/z 1030.6, 1044.7, 1058.7, and 1072.7 were attributable to the sodium adduct of pumilacidins (Figure 4,
Table 4) [15].
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Li o eptide [M + Na]+ (m/z) Isoforms
Pumilacidin
1030.6 C13 [Val7]
1044.7 C14 [Val7], C13 [Leu/Ile7]
1058.7 C15 [Val7] (pumilacidin B) a, C14 [Leu/Ile7]
1072.7 C16 [Val7] (pumilacidin F/G) a, C15 [Leu/Ile7] (pumilacidin A) a
1086.7 C17 [Val7] (pumilacidin D) a, C16 [Leu/Ile7] (pumilacidin E) a
1100.7 C18 [Val7], C17 [Leu/Ile7] (pumilacidin C) a
a See reference [15] for the pumilacidin nomenclature.
Since some pumilacidin isoforms have the same m/z values, MS/MS analyses were necessary to
identify the amino acid sequence of the peptide portion [15,21,22]. The experiments were carried out
on the most abundant signals of the mass spectrum. As an example, Figure 5 displays the positive
ion MS/MS spectrum obtained from the precursor ion at m/z 1058.7. Through this experiment, it was
possible to identify two series of b+ fragment ions at m/z 959.9–846.7 and m/z 945.8–832.8, indicating
that at least two isoforms with Val or Leu/Ile at the C terminus, respectively, were present (Figure 5).
This was confirmed by the y+ fragment ions, since two different series at m/z 707.5–594.6–481.6 and
m/z 721.6–608.5–495.6 were found (Figure 5). These fragmentation patterns suggested that the signal
at m/z 1058.7 corresponded to the B isoform, with a C15(3OH) [20]; and to another isoform with a
C14(3OH). Similarly, the fragmentation patterns of parent ions at m/z 1044.7 and m/z 1072.7 indicated
the same amino acid sequences, with different hydroxylated fatty acids (Table 4). Since the signals
at m/z 1030.6, 1086.7, and 1100.7 displayed a low intensity, the corresponding structures reported in
Table 4 were suggested by analogy. Some of these pumilacidins have been already characterized [15],
as reported in Table 4. However, as far as we know, the isoforms containing 3-hydroxy-tridecanoic,
-tetradecanoic, and -octadecanoic fatty acids have not been reported yet.
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Figure 5. Positive ion MALDI-TOF MS/MS spectrum of the pumilacidin precursor ion at m/z 1058.7.
b+ and y+ fragment ions are reported for pumilacidin isoforms in the insert.
In conclusion, the NMR and MALDI-TOF MS/MS spectra indicated that the anti-Staphylococcus
activity was due to a mixture of lipopeptides with structures similar to those of pumilacidins
produced by strains of B. pumilus and B. safensis [12,15]. SF214 produced two isoforms of pumilacidin
corresponding in their heptapeptide sequences to the previously reported pumilacidins [15] and with
hydrophobic chains ranging in size between 13 and 18 carbon atoms (Table 4).
2.5. The srfA-sfp Locus of SF214
To characterize the pumilacidin biosynthetic pathway in SF214, we searched the SF214 genome
for homologs of genes coding for the NRPS responsible for the nonribosomal synthesis of surfactants
in bacilli. A srfA-sfp locus was identified in SF214, and the various genes of the locus showed a high
similarity (over 90%) with homologs of other pumilacidin-producing strains of the B. pumilus and
B. safensis species (Table 5).
Table 5. Genes and putative proteins involved in surfactin/pumilacidin synthesis in B. pumilus SF214,
B. pumilus SAFR-032, and B. safensis U17-1.
Genes Puta ive Encoded Protein
Protein Identity (%) a
B. pumilus SF214
vs. B. pumilus
SAFR-032
B. pumilus SF214
vs. B. safensis
U17-1
B. pumilus SAFR-032
vs. B. safensis
U17-1
srfAA surfactin synthase subunit 1 95 91 90
srf B surfactin synthase subunit 2 94 91 90
srfAC surfactin synthase subunit 3 95 93 91
orfX nonribosomal peptide synthetase 94 91 89
orfY nonribosomal peptide synthetase 94 92 90
srfAD surfactin synthase thioesterase subunit 94 89 87
1 hypothetical protein - 87 -
2 hypothetical protein - 89 -
3 hypothetical protein - 90 -
4 hypothetical protein - 84 -
5 hypothetical protein - 90 -
ycxC transporter 96 93 92
ycxD transcriptional regulator 95 93 93
sfp 4′-phosphopantetheinyl transferase 94 88 88
a The symbol “-” indicates the absence of the protein in B. pumilus SAFR-032.
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The srfA operon (Figure 6) was organized in six genes: srfAA, srfAB, and srfAC, coding for
the surfactin synthase subunits 1, 2, and 3 respectively; and srfAD, coding for a surfactin synthase
thioesterase subunit and two still-uncharacterized genes, orfX and orfY. These two genes are not
present in surfactin- or lychenisin-producing species [12] and are only found in strains of B. pumilus
and B. safensis that produce pumilacidins [12]. The presence of orfX/orfY is the main difference
between the srfA operon of the B. pumilus/B. safensis and that of the B. subtilis/B. amyloliquefaciens/
B. licheniformis group of surfactant-producing bacilli [12].
All six genes of the srfA operon of SF214 coded for putative proteins with the typical modular
organization of NRPS (Figure 7). In particular, srfAA-AC genes coded for proteins arranged in
modules of 10, 10, and 4 domains, respectively. In each module of SrfAA and SrfAB of SF214,
a condensation domain (C) was followed by an AMP-binding (AMP) and a peptidyl carrier (PCP)
domain. The tenth domain of both proteins of SF214 was an additional C domain (Figure 7), while in
other pumilacidin-producing bacteria, an epimerization (E) domain was present at the C-terminal part
of SrfAA and SrfAB [12]. SrfAC of SF214 had four domains, as in other pumilacidin-producing strains
(Figure 7). OrfX and OrfY were characterized by eight and seven domains, respectively. In SF214,
the seventh domain of OrfX was a C domain and not an E domain, as in other strains that produce
pumilacidins [12]; while OrfY and SrfAD showed the same organization as that of other B. pumilus or
B. safensis strains.
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Like in other lychenysin- or pumilacidin-producing bacteria, in SF214, the yxc operon is formed
by only two genes, ycxC and ycxD, and homologs of ycxAB genes of B. subtilis and B. amyloliquefaciens
are not found (Figure 6).
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With respect to the group of pumilacidin producers, an additional difference was observed in
SF214. It contained an insertion element between srfAD and ycxC, more commonly found in B. safensis
than in B. pumilus strains [12]; (Figure 6). The insertion element of SF214 coded for five putative
products, highly similar (84–87%) to those encoded by B. safensis strains (Table 5).
The presence of such an insertion element and the high similarity between the B. pumilus and
B. safensis species raised the possibility that SF214 was originally [17] misclassified as B. pumilus.
To address this point, we performed an accurate phylogenetic analysis based on the 16S RNA and gyrB
gene sequences. In both cases, the SF214 sequences shared the highest similarity with sequences of
B. pumilus strains (Figure 8), suggesting SF214 as being an isolate of B. pumilus. To confirm this finding,
the entire genome of B. pumilus SF214 was compared with the genomes of B. pumilus SAFR-032,
B. safensis KCTC, and B. safensis U17. The average nucleotide identity (ANI) values, reported in
parentheses, indicated that SF214 is more similar to B. pumilus SAFR-032 (94.87%) than to B. safensis
KCTC (92.44%) and B. safensis U17 (92.40%).
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3. Experimental Section
3.1. Bacterial Strains
Bacillus str i s r listed in Table S1 (Supplementary Materials). The antibacterial activity of these
strains was evaluated using a p nel of indicator strains: six r - siti ( tre tococc s faecalis,
Staphylococcus aureus, Bacillus egaterium, Listeria onocytogenes, ycobacterium s egmatis, and
Enterococcus faecalis) and five ra -negative (Escherichia coli, Salmonella enterica typhimurium,
Pseudo onas fluorescens, Shigella sonnei, and Citrobacter freundii) bacteria [25]. All bacteria were grown
in LB broth (8 g/L NaCl, 10 g/L tryptone, 5 g/L yeast extract) aerobically at 25 ◦C.
To characterize the anti icro ial r cti f SF214, t e strai as gro at 37 ◦C in different
edia, ith a ase f ( ifc s r l ti e i : ct trie t r t , l L, and
gS 4 0.25 g/L, sterilized at 121 ◦C for 30 min). To 1 L of this solution, 1 mL of each of the following
filter-sterilized solutions ere added: 1 ( 3)2, 10 mM nCl2 and 1 FeS 4; S7 (50
orpholinepropanesulfonic acid ( PS) (adjusted to 7.0 it ), 10 ( 4)2S 4, 5
potassiu phos ate ( 7.0), 2 l2, 0.9 a l2, 50 µ l2, 5 µ FeCl3, 10 µ ZnCl2,
2 µM thiamine hydrochloride, 20 mM sodium glutamate, 1% glucose, 0.1 g/mL phenylalanine,
and 0.1 mg/mL tryptophan); a d brain heart infusion (BHI: beef heart 5 g/L, calf brains 12.5 g/L,
Na2HPO4 2.5 g/L, glucose 2 g/L, peptone 10 g/L, and NaCl 5 g/L).
3.2. Filter-Sterilized and Size-Fractionated Supernatants
Baci lus pumilus SF214 [17] was grown in LB broth for 24 h at 37 ◦C; the culture as diluted and
used to inoculate fresh LB, Difco Sporulation (DS), or S7 edia. Ce ls of SF214 were then grown for
16 h at 25 ◦C, where not other ise specifi . T e c lt r g for 10 min at Room
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Temperature) and the supernatant filter-sterilized with a 0.22-µm filter (Millipore, Bedford, MA, USA).
The supernatants were size-fractionated (3-kDa and 10-kDa cutoff spin column; Centricon, Millipore).
Fractions were tested for antimicrobial activity and reported as the diameter (in millimeters) of the
inhibition halo in plate assays.
3.3. Antimicrobial Plate Assay
Antimicrobial activity was determined with the method described by Schillinger and Lüeke [26]
with the following modifications: 10 µL of each bacterial culture (strains listed in Table 1) in stationary
growth phase were spotted on the surface of a sterile LB agar plate and the spots air-dried. 100 µL
of an exponential culture of each of the indicator bacterial strains was mixed with 10 mL of soft agar
(0.7%) and poured over the plate. The plates were incubated aerobically overnight at 37 ◦C and the
inhibition halos were measured and reported in mm.
3.4. Stability of Antimicrobials at Different pH, Temperature, Chemical, and Enzyme Conditions
Enzymes (100 µg/mL) and 10% organic solvents (see Table 3) were added to 100 µL of culture
supernatant. Enzyme-treated samples were incubated 1 h at 37 ◦C (42 ◦C in the case of proteinase K)
and solvent-treated samples were incubated for 1 and 5 h at 25 ◦C, and subsequently, 10 µL aliquots
were tested for antimicrobial activity as described above. The effects of pH and heat (Tables 2 and 3)
on supernatants were analyzed by assaying the antimicrobial activity after 15 min of incubation at 60,
80, and 100 ◦C and after 1- and 5-h incubations at 30 ◦C in 50 mM phosphate buffer (pH 6.0), adjusted
to the various pH with HCl and NaOH.
3.5. Lipopeptide Purification and Preliminary Analysis
The fraction active against S. aureus was extracted three times with chloroform (v/v 1:1).
The organic phases were combined and concentrated in a rotary vacuum evaporator to obtain 18 mg.
The organic phase was fractionated on a C18 reverse phase column (Sigma, Aldrich, Italy, 30 mL,
40 cm × 0.5 cm, fraction volume 4 mL) and eluted with CH3CN/H2O, ranging from 10% to 100% of
CH3CN. The collected fractions were tested for antimicrobial activity and the active fraction, eluted
with 50% CH3CN, was preliminary analyzed by 1H NMR. The sample was dissolved in 0.5 mL
of DMSO-d6, and the 1H NMR spectrum was recorded at 298 K using a BrukerAvance 600 MHz
spectrometer equipped with a cryoprobe (Bruker Italia, Milano, Italy).
3.6. Characterization of Lipopeptide
MALDI-TOF spectra were acquired in reflector positive mode by using a SCIEX TOF/TOF™ 5800.
Fractions were dissolved in CHCl3/CH3OH (v/v 1:1) at a concentration of 1.0 mg/mL, and 0.5 µL of
the solution was mixed on the plate with 0.5 µL of a 20 mg/mL solution of 2,5-dihydroxy benzoic acid
in CH3CN/TFA 0.1 (v/v 7:3). The m/z values were measured in the range from m/z 500 to 5000.
MALDI TOF-MS/MS coupled with CID (Collision-Induced Dissociation) was used to analyze the
fragment ions of lipopeptides for further characterization of the amino acid sequence.
3.7. Bioinformatic Analysis
The genome of SF214 (PRJNA290581) was analyzed by searching for homologs of the srfA-sfp
locus of other biosurfactant-producing strains of the Bacillus spp. by using a BLAST analysis (http://
blast.ncbi.nlm.nih.gov/) [27]. The prediction of the protein structure for the products of the srfA operon
of SF214 was obtained by using the web server HMMER (https://www.ebi.ac.uk/Tools/hmmer/) [23].
For the phylogenetic analysis, the complete 16S ribosomal RNA (rRNA) and gyrase subunit B (gyrB)
gene sequences of SF214 and of closely related type strains of Bacillus species (from GenBank database)
were used to obtain two phylogenetic trees by using the web service “Phylogeny.fr” [24]. The genome
comparison and the analysis of ANI values were performed using Jspecies software [28,29].
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4. Conclusions
We report that a marine-isolated strain of B. pumilus, SF214, produces and secretes two molecules
with antimicrobial activity: a molecule smaller than 3 kDa active against Staphylococcus aureus
and a molecule larger than 10 kDa active against Listeria monocytogenes. The anti-Staphylococcus
molecule showed the typical expression pattern of secondary metabolites and we focused our
attention on the characterization of this small molecule. A mass spectrometry analysis identified
the anti-Staphylococcus molecule as a mixture of lipopeptides formed by a cyclic heptapeptide
with the sequence Glu-Leu-Leu-Leu-Asp-Leu-[(Leu/Ile)/Val] and a fatty acid with carbon chains
variable in length between 13 and 18 atoms. A similar structure is shared by biosurfactants of
the surfactin family [11]. Molecules of this family are nonribosomally synthesized and classified
as surfactins, produced by strains of B. subtilis and B. amyloliquefaciens; lichenysins, produced by
strains of B. licheniformis; and pumilacidins, produced by strains of B. pumilus and B. safensis [12].
These molecules all have very similar structures, with the heptapeptides sharing similar amino acid
sequences and the fatty acids having carbon chains of variable length (C12–C18) [12,20]. The surfactant
produced by SF214 has hydrophobic chains of highly variable length (C13–C18) and differs from
pumilacidins produced by other B. pumilus strains that are characterized by less variability, with chains
of C12–C14 [30] or C15–C17 [31].
Additional differences between SF214 and other pumilacidin-producing strains of B. pumilus
are in the organization of the sfrA-spf locus coding for the multimodular enzyme responsible for
the nonribosomal synthesis of the biosurfactant. The SrfA and SrfB proteins are organized in
10 modules, but the epimerization domain present at the C-terminal end of both proteins of other
pumilacidic-producing strains is replaced in SF214 by a condensation domain. Moreover, an insertion
element of 4684 bp, previously identified in members of the B. safensis species, is present in SF214
between srfAD and ycxC.
Understanding whether and how the differences observed in the srfA-sfp locus cause the minor
differences observed in the structure of the pumilacidin of SF214 with respect to those of other strains
of B. pumilus and B. safensis will be a challenging future perspective opened by this report.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/6/180/s1,
Table S1: Marine isolated strains of the Bacillus genus, Table S2: Antimicrobial plate assay with 20 mL of
filter-sterilized supernatant of SF214, Table S3: GenBank accession numbersa/locus tagb for the sequences of
SF214 and of closely related type strains of Bacillus species used in this studya.
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